Article Information
History
- November 1, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- N.L. Mason1,*,
- A. Szabo2,
- K.P.C. Kuypers1,
- P.A. Mallaroni1,
- R. de la Torre Fornell3,
- J.T. Reckweg1,
- D.H.Y. Tse1,
- N.R.P.W. Hutten1,
- A. Feilding4 and
- J.G. Ramaekers1
- 1Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, P.O. Box 616, 6200 MD Maastricht, the Netherlands
- 2Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; KG Jebsen Centre for Neurodevelopmental Disorders, University of Oslo, Oslo, Norway
- 3Integrative Pharmacology and Systems Neurosciences Research Group. Neurosciences Program. Hospital del Mar Medical Research Institute. Department of Medicine and Life Sciences (MELIS), Universitat Pompeu Fabra. Dr. Aiguader 88, 08003 Barcelona, Spain
- 4The Beckley Foundation, Beckley Park, Oxford, OX3 9SY, United Kingdom
- ↵* Corresponding author; email: natasha.mason{at}maastrichtuniversity.nl
Posted November 01, 2022.
Psilocybin induces acute and persisting alterations in immune status and the stress response in healthy volunteers
